Tuesday, June 6, 2017

Lung Therapeutics Gets $14.3M

Austin-based Lung Therapeutics, a pharmaceuticals company which is developing treatments for fibrosis, lung injury and related disease, has raised $14.3M in a Series B funding. The funding was led by Bios Partners, and also included the UT Horizon Fund. Lung Therapeutics said the new funding will go towards development of its drug technology and a multi-site trial in Australia and New Zealand. Brian Windsor is CEO of Lung Therapeutics. More information »